Larson Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.5K Sell
68
-4
-6% -$870 ﹤0.01% 2396
2026
Q2
$17.6K Buy
72
+7
+11% +$1.52K ﹤0.01% 2076
2026
Q1
$11K Sell
65
-4
-6% -$691 ﹤0.01% 2192
2025
Q4
$12.6K Buy
69
+25
+57% +$3.49K ﹤0.01% 1982
2025
Q3
$5.34K Buy
44
+43
+4,300% +$4.84K ﹤0.01% 2333
2025
Q2
$104 Hold
1
– – ﹤0.01% 3158
2025
Q1
$117 Buy
+1
New +$114 ﹤0.01% 2885

Other funds holding AXSM

Larson Financial Group's AXSM Position: Q3 2026 in Review

Larson Financial Group reduced its Axsome Therapeutics (AXSM) stake by 5.6% in Q3 2026, selling an estimated $870 and leaving 68 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

Larson Financial Group first reported a position in AXSM in Q1 2025 and has held it in 7 quarters since. The position peaked at $17.6K in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Larson Financial Group held 68 shares of Axsome Therapeutics worth $12.5K as of Q3 2026.
  • Larson Financial Group sold 4 Axsome Therapeutics shares in Q3 2026, an estimated $870.
  • Axsome Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #2396 holding.
  • Larson Financial Group first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Larson Financial Group's Axsome Therapeutics position peaked at $17.6K in Q2 2026.
  • 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.